Bronchiolitis obliterans syndrome due to donor-specific HLA-antibodies

Tissue Antigens

Volumn 86, Issue 3, 2015, Pages 178-185

  Kauke, T ^a   Kneidinger, N ^a   Martin, B ^a   Dick, A ^a   Schneider, C ^a   Schramm, R ^a   Meimarakis, G ^a   Preissler, G ^a   Eickelberg, O ^b   von Dossow, V ^a   Behr, J ^a   Hatz, R ^a   Neurohr, C ^a   Winter, H ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Bronchiolitis obliterans syndrome; Chronic lung allograft dysfunction; Human leukocyte antigen antibodies; Humoral rejection; Lung transplantation

Indexed keywords

AZATHIOPRINE; COMPLEMENT COMPONENT C4D; CORTICOSTEROID; CYCLOSPORIN; FOSCARNET; GANCICLOVIR; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G; MYCOPHENOLATE MOFETIL; TACROLIMUS; VALGANCICLOVIR; ANTIBODY; HLA ANTIGEN;

ACUTE GRAFT REJECTION; ADULT; ANTIBODY MEDIATED REJECTION; ARTERIAL OXYGEN TENSION; ARTICLE; BRONCHIOLITIS OBLITERANS; CYTOMEGALOVIRUS INFECTION; FEMALE; FORCED EXPIRATORY VOLUME; GRAFT RECIPIENT; GRAFT SURVIVAL; HIGH RISK PATIENT; HLA TYPING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; PLASMAPHERESIS; PRIMARY GRAFT DYSFUNCTION; PRIORITY JOURNAL; DONOR; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIBODIES; BRONCHIOLITIS OBLITERANS; FEMALE; HLA ANTIGENS; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; TISSUE DONORS;

EID: 84938955924     PISSN: 00012815     EISSN: 13990039     Source Type: Journal    
DOI: 10.1111/tan.12626     Document Type: Article

References (38)

1. Yusen RD, Christie JD, Edwards LB et al. The registry of the international society for heart and lung transplantation: thirtieth adult lung and heart-lung transplant report-2013; focus theme: age. J Heart Lung Transplant 2013: 32: 965-78.
2. Weigt SS, DerHovanessian A, Wallace WD et al. Bronchiolitis obliterans syndrome: the Achilles' heel of lung transplantation. Semin Respir Crit Care Med 2013: 34: 336-51.
3. Girnita AL, Duquesnoy R, Yousem SA et al. HLA-specific antibodies are risk factors for lymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005: 5: 131-8.
4. Witt CA, Gaut JP, Yusen RD et al. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2013: 32: 1034-40.
5. Morrell MR, Patterson GA, Trulock EP, Hachem RR. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2009: 28: 96-100.
6. Girnita AL, Lee TM, McCurry KR et al. Anti-human leukocyte antigen antibodies, vascular C4d deposition and increased soluble c4d in broncho-alveolar lavage of lung allografts. Transplantation 2008: 86: 342-7.
7. Ionescu DN, Girnita AL, Zeevi A et al. C4d deposition in lung allografts is associated with circulating anti-HLA alloantibody. Transpl Immunol 2005: 15: 63-8.
8. Tait BD, Süsal C, Gebel HM et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013: 95: 19-47.
9. Amico P, Hönger G, Mayr M, Steiger J, Hopfer H, Schaub S. Clinical relevance of pretransplant donor-specific HLA antibodies detected by single-antigen flow-beads. Transplantation 2009: 87: 1681-8.
10. Caro-Oleas JL, González-Escribano MF, Gentil-Govantes MÁ et al. Clinical relevance of anti-HLA donor-specific antibodies detected by Luminex assay in the development of rejection after renal transplantation. Transplantation 2012: 94: 338-44.
11. Kim M, Townsend KR, Wood IG et al. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med 2014: 189: 1234-9.
12. Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2014: 33: 1273-81.
13. Shah AS, Nwakanma L, Simpkins C, Williams J, Chang DC, Conte JV. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10, 000 patients. Ann Thorac Surg 2008: 85: 1919-24.
14. Hachem RR. Antibodies to human leukocyte antigens in lung transplantation. Clin Transpl 2011: 327-32.
15. Paantjens AWM, van de Graaf EA, Kwakkel-van Erp JM et al. The Induction of IgM and IgG Antibodies against HLA or MICA after lung transplantation. Pulm Med 2011: 2011: 432169.
16. Morrell MR, Pilewski JM, Gries CJ et al. De novo donor-specific HLA antibodies are associated with early and high-grade bronchiolitis obliterans syndrome and death after lung transplantation. J Heart Lung Transplant 2014: 33: 1288-94.
17. Thabut G, Mal H, Cerrina J et al. Graft ischemic time and outcome of lung transplantation: a multicenter analysis. Am J Respir Crit Care Med 2005: 171: 786-91.
18. Neurohr C, Huppmann P, Samweber B et al. Prognostic value of bronchoalveolar lavage neutrophilia in stable lung transplant recipients. J Heart Lung Transplant 2009: 28: 468-74.
19. Neurohr C, Huppmann P, Leuschner S et al. Usefulness of exhaled nitric oxide to guide risk stratification for bronchiolitis obliterans syndrome after lung transplantation. Am Transplant 2011: 11: 129-37.
20. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, european community for steel and coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993: 16: 5-40.
21. Christie JD, Carby M, Bag R, Corris P, Hertz M, Weill D. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction part II: definition. A consensus statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2005: 24: 1454-9.
22. Yousem SA, Berry GJ, Cagle PT et al. Revision of the 1990 working formulation for the classification of pulmonary allograft rejection: Lung Rejection Study Group. J Heart Lung Transplant 1996: 15: 1-15.
23. Takemoto SK, Zeevi A, Feng S et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004: 4: 1033-41.
24. Kneidinger N, Giessen C, von Wulffen W et al. Trip to immunity: resistant cytomegalovirus infection in a lung transplant recipient. Int J Infect Dis 2014: 28: 140-2.
25. Campbell P. Clinical relevance of human leukocyte antigen antibodies in liver, heart, lung and intestine transplantation. Curr Opin Organ Transplant 2013: 18: 463-9.
26. Liu C, Wetter L, Pang S, Phelan DL, Mohanakumar T, Morris GP. Cutoff values and data handling for solid-phase testing for antibodies to HLA: effects on listing unacceptable antigens for thoracic organ transplantation. Hum Immunol 2012: 73: 597-604.
27. Brugière O, Suberbielle C, Thabut G et al. Lung transplantation in patients with pretransplantation donor-specific antibodies detected by Luminex assay. Transplantation 2013: 95: 761-5.
28. Smith JD, Ibrahim MW, Newell H et al. Pre-transplant donor HLA-specific antibodies: characteristics causing detrimental effects on survival after lung transplantation. J Heart Lung Transplant 2014: 33: 1074-82.
29. Lyu DM, Grazia TJ, Benson AB, Cagle LR, Freed BM, Zamora MR. Pre-transplant presence of antibodies to MICA and HLA class I or II are associated with an earlier onset of bronchiolitis obliterans syndrome in lung transplant recipients. Clin Transpl 2012: 237-46.
30. Ius F, Sommer W, Tudorache I et al. Early donor-specific antibodies in lung transplantation: Risk factors and impact on survival. J Heart Lung Transplant 2014: 33: 1255-63.
31. Jackups R, Canter C, Sweet SC, Mohanakumar T, Morris GP. Measurement of donor-specific HLA antibodies following plasma exchange therapy predicts clinical outcome in pediatric heart and lung transplant recipients with antibody-mediated rejection. J Clin Apher 2013: 28: 301-8.
32. Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013: 32: 70-7.
33. Snyder LD, Gray AL, Reynolds JM et al. Antibody desensitization therapy in highly sensitized lung transplant candidates. Am J Transplant 2014: 14: 849-56.
34. DeNicola MM, Weigt SS, Belperio JA, Reed EF, Ross DJ, Wallace WD. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant 2013: 32: 326-32.
35. Haas M, Sis B, Racusen LC et al. Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant 2014: 14: 272-83.
36. Yousem SA, Zeevi A. The histopathology of lung allograft dysfunction associated with the development of donor-specific HLA alloantibodies. Am J Surg Pathol 2012: 36: 987-92.
37. Loupy A, Lefaucheur C, Vernerey D et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013: 26: 1215-26.
38. Zeevi A, Lunz J, Feingold B et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant 2013: 32: 98-105.